← Back to all trials
Recruiting
NCT07204275
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
Conditions: Primary Membranous Nephropathy
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: PHASE2, PHASE3
Enrollment: 176
Sponsor: Vertex Pharmaceuticals Incorporated
Location: Renal Associates Montgomery Alabama
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).
Eligibility Criteria
Key Inclusion Criteria:
• Diagnosed with pMN with confirmatory historical biopsy. If no historical biopsy was performed that confirmed pMN, a biopsy can be performed during Screening to confirm eligibility
Key Exclusion Criteria:
• Hypersensitivity to investigational medicinal product or to any of its excipients
Other protocol defined Inclusion/Exclusion criteria will apply
Source: ClinicalTrials.gov (NCT07204275). StuddyBuddy aggregates publicly available trial information.
